The role of the Fluorescence In Situ Hybridization Probe is evolving in parallel with the rise of Next-Generation Sequencing (NGS) technologies. While NGS provides broad, high-resolution sequence data across the entire genome, FISH retains its distinct advantage as the gold standard for visually confirming the location and physical presence of specific, large-scale chromosomal rearrangements.

In a clinical workflow, NGS might be used to initially screen for and identify novel or complex chromosomal abnormalities. Once a critical translocation or gene fusion is identified via sequencing, a custom-designed FISH probe can be created to visually confirm the finding in a cell line or patient sample, ensuring high diagnostic confidence. Furthermore, FISH is often faster and more cost-effective for confirming a single, known recurrent abnormality than running a full sequencing panel.

This complementary relationship ensures that FISH is not replaced by, but rather integrated with, sequencing technology, maintaining its vital role in the diagnostic pipeline. The continuous need for a rapid, visual confirmation tool secures the position of the probe in the integrated diagnostics segment of the molecular supplies surrounding the Fluorescence In Situ Hybridization Probe Market environment.

FAQ 1: Why is FISH still necessary when Next-Generation Sequencing (NGS) is available? FISH is necessary because it is the gold standard for visually confirming the physical presence, location, and cellular distribution of specific, large-scale chromosomal rearrangements identified by NGS.

FAQ 2: How do the two technologies typically work together in a clinical workflow? NGS is often used for broad screening and discovery, while a custom FISH probe is subsequently designed to visually and quickly confirm the clinical significance of a specific finding in the patient's cells.